Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Mineralys Therapeutics priced a $150 million underwritten public offering of 5.66 million shares at $26.50 per share. The company intends to use the net proceeds to fund a portion of the $200 million upfront payment required to repurchase royalty obligations from Tanabe Pharma Corporation.
Key figures
- Deal Value Usd
- 150000000
- Offering Price
- 26.5
- Shares Offered
- 5660378
- Debt facility size
- 500000000
- Royalty repurchase upfront
- 200000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.